Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5 [0.03%]
快速工程化SARS-CoV-2治疗性抗体以增加对包括BQ.1.1、CA.3.1、CH.1.1、XBB.1.16和XBB.1.5在内的变体的中和广度
Kevin C Entzminger,Jonathan K Fleming,Paul D Entzminger et al.
Kevin C Entzminger et al.
SARS-CoV-2 Omicron variant XBB.1.5 has shown extraordinary immune escape even for fully vaccinated individuals. There are currently no approved antibodies that neutralize this variant, and continued emergence of new variants puts immunocomp...
Preclinical evaluation of ISH0339, a tetravalent broadly neutralizing bispecific antibody against SARS-CoV-2 with long-term protection [0.03%]
ISH0399的临床前评估，一种针对SARS-CoV-2的四价广谱中和双特异性抗体，具有长期保护作用
Huabing Yang,Yuxin Chen,Dongcheng Jiang et al.
Huabing Yang et al.
Background: Ending the global COVID-19 pandemic requires efficacious therapies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nevertheless, the emerging Omicron sublineages largely escaped the neutr...
Beyond antibody fucosylation: α-(1,6)-fucosyltransferase (Fut8) as a potential new therapeutic target for cancer immunotherapy [0.03%]
抗体岩藻糖基化之外：α-(1,6)-岩藻糖基转移酶(Fut8)可能是癌症免疫治疗的新潜在药物靶点
Changchuin Mao,Jun Li,Lili Feng et al.
Changchuin Mao et al.
Aberrant post-translational glycosylation is a well-established hallmark of cancer. Altered core fucosylation mediated by α-(1,6)-fucosyltransferase (Fut8) is one of the key changes in tumor glycan patterns that contributes to neoplastic t...
Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method [0.03%]
一种高通量单B细胞克隆技术促进SARS-CoV-2中和抗体的发展
Yang Dou,Ke Xu,Yong-Qiang Deng et al.
Yang Dou et al.
Background: Rapid and efficient strategies are needed to discover neutralizing antibodies (nAbs) from B cells derived from virus-infected patients. Method...
Design of a chimeric ACE-2/Fc-silent fusion protein with ultrahigh affinity and neutralizing capacity for SARS-CoV-2 variants [0.03%]
一种针对SARS-CoV-2变异毒株的超高亲和力及中和能力的嵌合ACE-2/Fc型融合蛋白的设计
Neil M Bodie,Rina Hashimoto,David Connolly et al.
Neil M Bodie et al.
Background: As SARS-CoV-2 continues to mutate into Variants of Concern (VOC), there is growing and urgent need to develop effective antivirals to combat COVID-19. Monoclonal antibodies developed earlier are no longer capa...
Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics [0.03%]
早期发现阶段的可开发性评估以促进抗体类药物的研发
Weijie Zhang,Hao Wang,Nan Feng et al.
Weijie Zhang et al.
Developability refers to the likelihood that an antibody candidate will become a manufacturable, safe and efficacious drug. Although the safety and efficacy of a drug candidate will be well considered by sponsors and regulatory agencies, de...
Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15R α complex [0.03%]
IAP0971的临床前评估，这是一种新型免疫细胞因子，可特异性结合PD1并融合IL15/IL15Rα复合物
Jihong Chen,Ziyou Shen,Xiaoling Jiang et al.
Jihong Chen et al.
Background: Currently, cytokine therapy for cancer has demonstrated efficacy in certain diseases but is generally accompanied by severe toxicity. The field of antibody-cytokine fusion proteins (immunocytokines) arose to t...
Comparative Assessment of the Binding and Neutralisation Activity of Bispecific Antibodies Against SARS-CoV-2 Variants [0.03%]
针对SARS-CoV-2变异株的双特异性抗体的结合和中和活性的比较评估
Alexis Q Dean,Charles B Stauft,Julianne D Twomey et al.
Alexis Q Dean et al.
Background: Neutralising antibodies against SARS-CoV-2 are a vital component in the fight against COVID-19 pandemic, having the potential of both therapeutic and prophylactic applications. Bispecific antibodies (BsAbs) ag...
Ceramic hydroxyapatite chromatography plays a critical role in bispecific antibody purification process for impurity removal [0.03%]
陶瓷羟基磷灰石层析在双特异性抗体纯化过程中去杂质起着关键作用
Jessica A Waller,Ji Zheng,Rachel Dyer et al.
Jessica A Waller et al.
Background: Significant challenges exist in downstream purification of bispecific antibodies (BsAbs) due to the complexity of BsAb architecture. A unique panel of mispaired species can result in a higher level of product-...
A novel humanized Chi3l1 blocking antibody attenuates acetaminophen-induced liver injury in mice [0.03%]
新型人源化Chi3l1阻断抗体减轻小鼠由对乙酰氨基酚引起的肝损伤
Leike Li,Yankai Wen,Daniel Wrapp et al.
Leike Li et al.
Acetaminophen (APAP) overdose is a leading cause of acute liver injury in the USA. The chitinase 3-like-1 (Chi3l1) protein contributes to APAP-induced liver injury (AILI) by promoting hepatic platelet recruitment. Here, we report the develo...